Immunic names Chitrang Davé CDO

Immunic has added a new C-suite role as it moves closer to late-stage clinical and regulatory milestones. The New York-based biotech said on September 1 that it appointed Chitrang Davé as chief data and digital officer, effective immediately, with responsibility for building an enterprise-wide data and digital organization. The company said the role was created to support a “commercial-ready data ecosystem” ahead of potential NDA submission and commercialization. Davé will report to Chief Executive Officer Erik Lundgren and join Immunic’s executive leadership team. (prnewswire.com) ### Why is a late-stage biotech creating a chief data and digital officer role now? Immunic said the new post is tied to its transition from late-stage clinical development toward commercial readiness. The company said Davé will oversee data systems, analytics, artificial intelligence and digital strategy across a unified organization spanning data science, data engineering, data management and digital capabilities. Erik Lundgren said in the company’s announcement that Immunic has “pivotal trial readouts ahead” and potential NDA filing and commercialization “on the horizon.” Lundgren said the company wanted a modern data and digital foundation that could support clinical execution and scalable commercial capabilities. (prnewswire.com) ### What, specifically, will Davé be responsible for? Davé’s remit covers both research and commercial functions rather than a narrow IT brief. Immunic said he will centralize data and digital capabilities across the company and establish enterprise-wide systems intended to support development, regulatory preparation and launch planning. (prnewswire.com) Chitrang Davé said in the announcement that technology, data and AI could help “amplify the speed and agility of a focused biotech,” while also accelerating clinical execution and building scalable commercial capabilities. (prnewswire.com) The company framed the hire as part of its preparation for the next phase of growth rather than a change to its clinical strategy. ### What is Immunic preparing for in its pipeline? Immunic describes itself as a late-stage biotechnology company developing oral therapies for neurologic diseases. (prnewswire.com) Third-party summaries of the appointment said the company is building the role as it advances vidofludimus calcium, its lead multiple sclerosis program, toward possible regulatory and commercial milestones. A separate Immunic announcement said the company will host a virtual relapsing multiple sclerosis R&D day on September 9, 2026. (prnewswire.com) That event is set to focus on the company’s MS program and gives investors and industry watchers a near-term point to assess how management is positioning the business ahead of expected trial and filing steps. ### What does this tell us about how biotech companies are organizing? The newly created role places data, analytics and digital operations at the executive level rather than leaving them inside separate technical teams. (ca.finance.yahoo.com) Immunic said the job combines data science, engineering, management and digital capabilities in one organization, a structure aimed at linking clinical development work with regulatory preparation and commercialization. (immunic.com) That matters because regulatory submissions and launches depend on more than trial results alone. Immunic’s language around a “commercial-ready data ecosystem” indicates the company wants its clinical, operational and future commercial data infrastructure in place before a filing decision rather than after one. That framing came directly from the company’s September 1 statement. ### What comes next for Immunic and Davé? September 9 is the next named date on Immunic’s calendar. (marketscreener.com) The company’s virtual relapsing multiple sclerosis R&D day is expected to provide more detail on its lead program and the milestones management sees ahead. Davé’s appointment took effect on September 1, and Immunic said he joins the executive leadership team as the company prepares for potential NDA submission and commercialization. (immunic.com) (prnewswire.com)